1'-(4-fluorophenyl)-2-methyl-1'H,2H-3,4'-bipyrazole | 1356997-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1'-(4-fluorophenyl)-2-methyl-1'H,2H-3,4'-bipyrazole
• 英文别名: 1'-(4-Fluorophenyl)-2-methyl-1'H,2H-3,4'-bipyrazole；1-(4-fluorophenyl)-4-(2-methylpyrazol-3-yl)pyrazole
• CAS: 1356997-69-7
• 化学式: C₁₃H₁₁FN₄
• 分子量: 242.256
• InChiKey: ALOLFVSMGRYZDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  35.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-(4-氟苯基)吡唑-4-硼酸 、 5-碘-1-甲基-1H-吡唑 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 水 、 乙酸乙酯 、 甲苯 为溶剂， 反应 4.0h， 以450 mg的产率得到1'-(4-fluorophenyl)-2-methyl-1'H,2H-3,4'-bipyrazole
  参考文献：
  名称：

  HETEROARYL-PYRAZOLE DERIVATIVE

  摘要：

  公式[I]所代表的化合物及其药学上可接受的盐是一种新颖的化合物及其药学上可接受的盐，对II类代谢型谷氨酸（mGlu）受体具有拮抗活性，并且作为一种新型预防或治疗剂对情绪障碍（抑郁症、双相情感障碍等）、焦虑障碍（广泛性焦虑障碍、恐慌障碍、强迫症、社交焦虑障碍、创伤后应激障碍、特定恐惧障碍、急性应激障碍等）、精神分裂症、阿尔茨海默病、认知障碍、痴呆、药物依赖、抽搐、颤抖、疼痛、睡眠障碍等疾病具有有效性。

  公开号：

  US20130137865A1

文献信息

• HETEROARYL-PYRAZOLE DERIVATIVE
  申请人：Nakamura Toshio

  公开号：US20130137865A1

  公开（公告）日：2013-05-30

  A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

  公式[I]所代表的化合物及其药学上可接受的盐是一种新颖的化合物及其药学上可接受的盐，对II类代谢型谷氨酸（mGlu）受体具有拮抗活性，并且作为一种新型预防或治疗剂对情绪障碍（抑郁症、双相情感障碍等）、焦虑障碍（广泛性焦虑障碍、恐慌障碍、强迫症、社交焦虑障碍、创伤后应激障碍、特定恐惧障碍、急性应激障碍等）、精神分裂症、阿尔茨海默病、认知障碍、痴呆、药物依赖、抽搐、颤抖、疼痛、睡眠障碍等疾病具有有效性。
• Ethinyl-pyrazole derivative
  申请人：Nakamura Toshio

  公开号：US08642626B2

  公开（公告）日：2014-02-04

  Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.

  提供的是一种由式[I]所表示的新化合物，或其药学上可接受的盐，该化合物具有对群体II代谢型谷氨酸（m-Glu）受体的拮抗活性。该化合物或其药学上可接受的盐可用作预防或治疗新的情绪障碍（抑郁症和双相障碍）、焦虑症（广泛性焦虑症、恐慌症、强迫症、社交焦虑症、创伤后应激障碍、特定恐惧症和急性应激障碍）、精神分裂症、阿尔茨海默病、认知功能障碍、痴呆、药物依赖、惊厥、震颤、疼痛、睡眠障碍等疾病的预防或治疗剂。
• US8642626B2
  申请人：——

  公开号：US8642626B2

  公开（公告）日：2014-02-04
• ETHINYL-PYRAZOLE DERIVATIVE
  申请人：Nakamura Toshio

  公开号：US20130123500A1

  公开（公告）日：2013-05-16

  Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.

  提供的是一种由化学式[I]表示的新化合物，或者其在药学上可接受的盐，具有对抗第二组代谢型谷氨酸（m-Glu）受体的拮抗活性。该化合物或其药学上可接受的盐可用作预防或治疗剂，用于诸如新的情绪障碍（抑郁和双相障碍）、焦虑障碍（广泛性焦虑障碍、恐慌障碍、强迫症、社交焦虑障碍、创伤后应激障碍、特定恐惧症和急性应激障碍）、精神分裂症、阿尔茨海默病、认知功能障碍、痴呆、药物依赖、癫痫、震颤、疼痛、睡眠障碍等疾病。